Results 261 to 270 of about 2,670,563 (294)

Endocrine treatment in breast cancer: Cure, resistance and beyond

Cancer Treatment Reviews, 2016
Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a ...
Martine Piccart, Benita Katzenellenbogen, Dimitrios Zardavas   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Management of endocrine resistant breast cancer

British Menopause Society Journal, 2004
Metastatic breast cancer (MBC) may present de novo but more commonly develops in women initially presenting with early breast cancer despite the widespread use of adjuvant hormonal and cytotoxic chemotherapy. MBC is incurable. Hormone sensitive MBC eventually becomes resistant to endocrine therapy in most women.
Sundar, Santhanam, DeCatris, Marios, O'Byrne, Kenneth   +2 more
openaire   +3 more sources

Endocrine responses to resistance exercise

Medicine & Science in Sports & Exercise, 1988
The purpose of this brief review is to examine resistance training responses of selected hormones related to acute stress and growth promoting actions. Hormonal mechanisms appear to be involved with both short-term homeostatic control and long-term cellular adaptations.
openaire   +2 more sources

New agents for endocrine resistance in breast cancer

Breast, 2017
Estrogen receptor positive (ER+) and HER2-negative (HER2-) breast cancer (BC) is the most common BC subtype, defined by expression of the ER and absence of HER2 amplification.
Michail Ignatiadis, Christian Maurer, Dimitrios Zardavas   +2 more
exaly   +2 more sources

Resistance to endocrine therapy in breast cancer

Cancer Chemotherapy and Pharmacology, 2005
Endocrine therapy is the treatment of choice for patients with breast cancer expressing estrogen receptor (ER) and/or progesterone receptor. The efficacy of endocrine therapy is well established in the prevention, adjuvant and metastatic settings. However, either de novo or acquired resistance is frequently observed.
openaire   +2 more sources

Molecular Characterization of Endocrine Resistance.

Cancer Research, 2009
Abstract Background. Tamoxifen (TAM), anastrozole (ANA), letrozole (LET), and exemestane (EXE) are major drugs to treat estrogen (E)-dependent breast cancer. Although they are effective, disease recurrence often occurs as a result of acquired resistance to them. To unravel the mechanisms involved, MCF-7aro cell lines resistant to each of
S. Chen, S. Masri, H. Chan, K. Petrossian, S. Phung, Y. Yuan, H. Li, C. Kowolik   +7 more
openaire   +1 more source

Nonendocrine Pathways and Endocrine Resistance

Clinical Cancer Research, 2004
Abstract An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with ...
Robert I. Nicholson, Iain R. Hutcheson, Janice M. Knowlden, Helen E. Jones, Maureen E. Harper, Nicola Jordan, Steve E. Hiscox, Denise Barrow, Julia M. W. Gee   +8 more
openaire   +1 more source

Endocrine Resistance in Advanced Breast Cancer

Acta Oncologica, 1996
Although about half of patients with advanced breast cancer show either an objective response or disease stabilization on first line endocrine therapy, virtually all eventually relapse. Few of those patients that fail to respond to first-line treatment, respond to challenge with a second agent.
openaire   +2 more sources

Mechanisms of resistance to endocrine therapies for breast cancer

hmbci, 2012
Abstract Breast cancer is the most frequently diagnosed cancer in women and 70% of the cases are hormone-dependent. The presence of ERα is one of the most important prognostic factors predictive of response to endocrine therapy in human breast cancers.
Pierre, Heudel, Paul, Vilquin, Olivier, Tredan, Isabelle, Ray-Coquard, Jean-Paul, Guastalla, Isabelle, Treilleux, Thomas, Bachelot   +6 more
openaire   +2 more sources

Biological determinants of endocrine resistance in breast cancer

Nature Reviews Cancer, 2009
Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation ...
Elizabeth A, Musgrove, Robert L, Sutherland   +1 more
openaire   +2 more sources